Akeso/Summit’s Bispecific Ivonescimab Bests Keytruda In 1L NSCLC

China-Only Study But Big Implications?

 
• By Dexter Jie Yan
  
Cancer survival
Ivonescimab comes out strong in China head-to-head trial with Keytruda in first-line NSCLC • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia